Forest Laboratories, Inc. (NYSE: FRX) announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Lexapro (escitalopram oxalate) for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, 12 – 17 years of age. Lexapro is only the second antidepressant to be approved for the treatment of MDD in adolescents, a medical condition that affects approximately 2 million adolescents in the U.S.
Popularity: unranked [?]
Related posts:
- Forest Laboratories, Inc. Announces Positive Results Of LEXAPRO(R) Phase III Study In Adolescents With Major Depression
- Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval For Generic Lexapro(R)
- Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms In Adolescents
- U.S. Food And Drug Administration Approves ABILIFY(R) (aripiprazole) As The First Medication For Add-On Treatment Of Major Depressive Disorder (MDD)
- Lexapro Loses First-Line Position For The Treatment Of Major Depression
Comments
No Responses to “Forest Laboratories, Inc. Announces FDA Approval Of Lexapro(R) For The Treatment Of Major Depressive Disorder In Adolescents”